ID   SHIN-3
AC   CVCL_A670
SY   SHIN3; Shin3
DR   cancercelllines; CVCL_A670
DR   Cosmic; 877481
DR   Cosmic; 945374
DR   Cosmic; 1152561
DR   Cosmic; 1526883
DR   Cosmic; 2482713
DR   GEO; GSM459739
DR   Progenetix; CVCL_A670
DR   Wikidata; Q54953343
RX   CelloPub=CLPUB00115;
RX   DOI=10.5795/jjscc.27.926;
RX   PubMed=2314830;
RX   PubMed=2469292;
RX   PubMed=8718548;
RX   PubMed=8980248;
RX   PubMed=15677628;
CC   Population: Japanese.
CC   Doubling time: 48.3 hours (Note=At 12th passage), 26.7 hours (Note=At 20th passage) (PubMed=2314830).
CC   Sequence variation: Gene deletion; HGNC; HGNC:1787; CDKN2A; Zygosity=Homozygous (PubMed=8980248).
CC   Sequence variation: Mutation; HGNC; HGNC:6407; KRAS; Simple; p.Gly12Ser (c.34G>A); ClinVar=VCV000012584; Zygosity=Unspecified (PubMed=8980248).
CC   Derived from site: In situ; Ovary; UBERON=UBERON_0000992.
DI   NCIt; C7978; Ovarian serous cystadenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   56Y
CA   Cancer cell line
DT   Created: 06-06-12; Last updated: 19-12-24; Version: 18
//
RX   CelloPub=CLPUB00115;
RA   Kiyozuka Y., Noda T., Maruyama M., Adachi S., Ichijo M., Maeda H.,
RA   Moriyama I., Imai S.;
RT   "Establishment and characterization of CA125 and TPA producing human
RT   ovarian serous cystadenocarcinoma cell line (SHIN-3).";
RL   Hum. Cell 1:334-335(1988).
//
RX   DOI=10.5795/jjscc.27.926;
RA   Kiyozuka Y., Imai S., Noda T., Morimoto J., Moriyama I., Ichijo M.,
RA   Tsubura Y.;
RT   "Establishment and characterization of human ovarian serous
RT   cystadenocarcinoma cell line (SHIN-3) which produces CA 125 and TPA in
RT   vitro.";
RL   Nihon Rinsho Saibo Gakkai Zasshi 27:926-935(1988).
//
RX   PubMed=2314830; DOI=10.1159/000226813;
RA   Imai S., Kiyozuka Y., Maeda H., Noda T., Hosick H.L.;
RT   "Establishment and characterization of a human ovarian serous
RT   cystadenocarcinoma cell line that produces the tumor markers CA-125
RT   and tissue polypeptide antigen.";
RL   Oncology 47:177-184(1990).
//
RX   PubMed=2469292; DOI=10.1111/j.1440-1827.1989.tb02401.x;
RA   Imai S., Maeda H., Kiyozuka Y., Noda T., Moriyama I., Ichijo M.;
RT   "Characterization of the CA125 antigen secreted from a newly
RT   established human ovarian cancer cell line (SHIN-3).";
RL   Acta Pathol. Jpn. 39:43-49(1989).
//
RX   PubMed=8718548;
RA   Murakami F.;
RT   "Cytotoxic action of monoclonal antibodies OC125 and SH-9 on ovarian
RT   cancer cell lines.";
RL   Nihon Sanka Fujinka Gakkai Zasshi 48:125-132(1996).
//
RX   PubMed=8980248; DOI=10.1002/(SICI)1097-0215(19961220)69:6<466::AID-IJC8>3.0.CO;2-2;
RA   Ichikawa Y., Yoshida S., Koyama Y., Hirai M., Ishikawa T., Nishida M.,
RA   Tsunoda H., Kubo T., Miwa M., Uchida K.;
RT   "Inactivation of p16/CDKN2 and p15/MTS2 genes in different
RT   histological types and clinical stages of primary ovarian tumors.";
RL   Int. J. Cancer 69:466-470(1996).
//
RX   PubMed=15677628; DOI=10.1093/carcin/bgi032;
RA   Gorringe K.L., Chin S.-F., Pharoah P.D.P., Staines J.M., Oliveira C.,
RA   Edwards P.A.W., Caldas C.;
RT   "Evidence that both genetic instability and selection contribute to
RT   the accumulation of chromosome alterations in cancer.";
RL   Carcinogenesis 26:923-930(2005).
//